Lack of glycemic control in type two diabetes mellitus patients is associated with reduced serum epidermal growth factor level and increased insulin resistance

Al-Dwairi,Ahmed; Alfaqih,Mahmoud A.; Saadeh,Rami A.; Al-Shboul,Othman; Alqudah,Mohammad; Khanfar,Mariam; Khassawneh,Adi

doi:10.3892/br.2024.1883

Lack of glycemic control in type two diabetes mellitus patients is associated with reduced serum epidermal growth factor level and increased insulin resistance

Authors:
- Ahmed Al-Dwairi
- Mahmoud A. Alfaqih
- Rami A. Saadeh
- Othman Al-Shboul
- Mohammad Alqudah
- Mariam Khanfar
- Adi Khassawneh
View Affiliations

Affiliations: Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan, Department of Public Health and Community Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan
Published online on: October 29, 2024 https://doi.org/10.3892/br.2024.1883
Article Number: 5
Copyright: © Al-Dwairi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) is steadily increasing worldwide in an alarming fashion. Importantly, poor glycemic control is associated with development of various health sequalae's due to glucolipotoxicity, oxidative stress and increased inflammatory cytokines. The aim of the present study was to examine the effect of glycemic control on the relative abundance of inflammatory markers in patients with controlled and uncontrolled T2DM, and to test their association with the glycemic status in diabetic patients in Jordan. An observational cross‑sectional study design was used. Patients with T2DM with controlled diabetes [glycated hemoglobin (HbA_1c) ≤7.0%, n=110] and age‑, sex‑ and body mass index (BMI)‑matched uncontrolled diabetic patients (HbA_1c >7.0%, n=105) were recruited. An antibody membrane array was used to examine the relative abundance of inflammatory cytokines and growth factors in the sera of the study subjects, followed by enzyme‑linked immunosorbent assay (ELISA) to confirm the results. Fasting blood glucose, serum insulin, triglyceride and homeostatic model assessment for insulin resistance (HOMA‑IR) score were significantly elevated in the uncontrolled T2DM group (P<0.05). Antibody membrane array showed that serum epidermal growth factor (EGF) is significantly decreased in the uncontrolled T2DM group, and this was confirmed by ELISA (158.77±111.7 vs. 95.9±82.7 pg/ml, P=0.002). The binary logistic model was used to predict the likelihood of being uncontrolled diabetic based on EGF levels. After controlling for age, sex and BMI, EGF was statistically associated with diabetes control, where lower EGF levels predicted uncontrolled diabetes. Additionally, Pearson's product‑moment correlation showed a statistically significant negative correlation between EGF and HbA_1c (r=‑0.25, P<0.0001), and a positive correlation between HOMA‑IR and HbA_1c, (r=0.32, P<0.0001). The current data identify a novel link between serum EGF levels and the status of HbA_1c indicative of diabetic control.

View Figures

View References

1	International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org.
2	Awad SF, Huangfu P, Dargham SR, Ajlouni K, Batieha A, Khader YS, Critchley JA and Abu-Raddad LJ: Characterizing the type 2 diabetes mellitus epidemic in Jordan up to 2050. Sci Rep. 10(21001)2020.PubMed/NCBI View Article : Google Scholar
3	Kahn SE, Cooper ME and Del Prato S: Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet. 383:1068–1083. 2014.PubMed/NCBI View Article : Google Scholar
4	Tomic D, Shaw JE and Magliano DJ: The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 18:525–539. 2022.PubMed/NCBI View Article : Google Scholar
5	Trikkalinou A, Papazafiropoulou AK and Melidonis A: Type 2 diabetes and quality of life. World J Diabetes. 8:120–129. 2017.PubMed/NCBI View Article : Google Scholar
6	Aschner P: New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 132:169–170. 2017.PubMed/NCBI View Article : Google Scholar
7	American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S66–S76. 2020.PubMed/NCBI View Article : Google Scholar
8	Fiagbe J, Bosoka S, Opong J, Takramah W, Axame WK, Owusu R, Parbey PA, Adjuik M, Tarkang E and Kweku M: Prevalence of controlled and uncontrolled diabetes mellitus and associated factors of controlled diabetes among diabetic adults in the hohoe municipality of Ghana. Diabetes Manag. 7:343–354. 2017.
9	Siddiqui FJ, Avan BI, Mahmud S, Nanan DJ, Jabbar A and Assam PN: Uncontrolled diabetes mellitus: Prevalence and risk factors among people with type 2 diabetes mellitus in an Urban District of Karachi, Pakistan. Diabetes Res Clin Pract. 107:148–156. 2015.PubMed/NCBI View Article : Google Scholar
10	Cook MN, Girman CJ, Stein PP, Alexander CM and Holman RR: Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 28:995–1000. 2005.PubMed/NCBI View Article : Google Scholar
11	Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, Rentfro A, McCormick JB and Fisher-Hoch SP: Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional study. Cytokine. 57:136–142. 2012.PubMed/NCBI View Article : Google Scholar
12	Rohm TV, Meier DT, Olefsky JM and Donath MY: Inflammation in obesity, diabetes, and related disorders. Immunity. 55:31–55. 2022.PubMed/NCBI View Article : Google Scholar
13	Lee HY, Yea K, Kim J, Lee BD, Chae YC, Kim HS, Lee DW, Kim SH, Cho JH, Jin CJ, et al: Epidermal growth factor increases insulin secretion and lowers blood glucose in diabetic mice. J Cell Mol Med. 12:1593–1604. 2008.PubMed/NCBI View Article : Google Scholar
14	Song Z, Fusco J, Zimmerman R, Fischbach S, Chen C, Ricks DM, Prasadan K, Shiota C, Xiao X and Gittes GK: Epidermal growth factor receptor signaling regulates β cell proliferation in adult mice. J Biol Chem. 291:22630–22637. 2016.PubMed/NCBI View Article : Google Scholar
15	Warzecha Z, Dembiński A, Konturek PC, Ceranowicz P and Konturek SJ: Epidermal growth factor protects against pancreatic damage in cerulein-induced pancreatitis. Digestion. 60:314–323. 1999.PubMed/NCBI View Article : Google Scholar
16	Ledeganck KJ, den Brinker M, Peeters E, Verschueren A, De Winter BY, France A, Dotremont H and Trouet D: The next generation: Urinary epidermal growth factor is associated with an early decline in kidney function in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract. 178(108945)2021.PubMed/NCBI View Article : Google Scholar
17	Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, et al: IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 183(109119)2022.PubMed/NCBI View Article : Google Scholar
18	Zhang J, Lin C, Jin S, Wang H, Wang Y, Du X, Hutchinson MR, Zhao H, Fang L and Wang X: The pharmacology and therapeutic role of cannabidiol in diabetes. Exploration (Beijing). 3(20230047)2023.PubMed/NCBI View Article : Google Scholar
19	Forbes JM and Cooper ME: Mechanisms of diabetic complications. Physiol Rev. 93:137–188. 2013.PubMed/NCBI View Article : Google Scholar
20	Cheng HT, Xu X, Lim PS and Hung KY: Worldwide epidemiology of diabetes-related end-stage renal disease, 2000-2015. Diabetes Care. 44:89–97. 2021.PubMed/NCBI View Article : Google Scholar
21	Galindo RJ, Trujillo JM, Low Wang CC and McCoy RG: Advances in the management of type 2 diabetes in adults. BMJ Med. 2(e000372)2023.PubMed/NCBI View Article : Google Scholar
22	Sun YM, Qu W, Liao JB, Chen L, Cao YJ and Li HL: Jiangtangjing ameliorates type 2 diabetes through effects on the gut microbiota and cAMP/PKA pathway. Tradit Med Res. 7(7)2022.
23	Riedel AA, Heien H, Wogen J and Plauschinat CA: Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy. 27:1102–1110. 2007.PubMed/NCBI View Article : Google Scholar
24	Boye KS, Lage MJ and Kiljański J: Time to failure on oral glucose-lowering agents for patients with type 2 diabetes: A retrospective cohort study. Diabetes Ther. 12:1463–1474. 2021.PubMed/NCBI View Article : Google Scholar
25	Meybosch S, De Monie A, Anné C, Bruyndonckx L, Jürgens A, De Winter BY, Trouet D and Ledeganck KJ: Epidermal growth factor and its influencing variables in healthy children and adults. PLoS One. 14(e0211212)2019.PubMed/NCBI View Article : Google Scholar
26	Isaka Y: Epidermal growth factor as a prognostic biomarker in chronic kidney diseases. Ann Transl Med. 4 (Suppl 1)(S62)2016.PubMed/NCBI View Article : Google Scholar
27	Roskoski R Jr: The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79:34–74. 2014.PubMed/NCBI View Article : Google Scholar
28	Jansen C, Lundquist I, Salehi A, Axelson J and Ohlsson B: Does epidermal growth factor participate in the regulation of glucose, insulin and glucagon levels? Eur Surg Res. 38:377–384. 2006.PubMed/NCBI View Article : Google Scholar
29	Baeyens L, De Breuck S, Lardon J, Mfopou JK, Rooman I and Bouwens L: In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells. Diabetologia. 48:49–57. 2005.PubMed/NCBI View Article : Google Scholar
30	Wang H, Gambosova K, Cooper ZA, Holloway MP, Kassai A, Izquierdo D, Cleveland K, Boney CM and Altura RA: EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells. BMC Mol Biol. 11(66)2010.PubMed/NCBI View Article : Google Scholar
31	Kasayama S, Ohba Y and Oka T: Epidermal growth factor deficiency associated with diabetes mellitus. Proc Natl Acad Sci USA. 86:7644–7648. 1989.PubMed/NCBI View Article : Google Scholar
32	Armstrong DG, Boulton AJM and Bus SA: Diabetic foot ulcers and their recurrence. N Engl J Med. 376:2367–2375. 2017.PubMed/NCBI View Article : Google Scholar
33	Wu X, He W, Mu X, Liu Y, Deng J, Liu Y and Nie X: Macrophage polarization in diabetic wound healing. Burns Trauma. 10(tkac051)2022.PubMed/NCBI View Article : Google Scholar
34	Araújo AP, Ribeiro R, Pereira D, Pinto D, Sousa B, Catarino R and Medeiros R: Exp Biol Med. (Maywood). 234:241–245. 2009.
35	Cacina C, Arikan S, Düzköylü Y, Doğan MB, Okay E, Turan S, Yaylim I and Isbir T: Analyses of EGF A61G gene variation and serum EGF level on gastric cancer susceptibility and clinicopathological parameters. Anticancer Res. 35:2709–2713. 2015.PubMed/NCBI
36	Trimal K, Shah T, Joshi K and Mulla G: Association of EGF A61G polymorphism and EGF expression with type 2 diabetes mellitus in Indian population. Gene Rep. 15(100384)2019.
37	Ju W, Nair V, Smith S, Zhu L, Shedden K, Song PXK, Mariani LH, Eichinger FH, Berthier CC, Randolph A, et al: Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med. 7(316ra193)2015.PubMed/NCBI View Article : Google Scholar
38	Wong RW and Guillaud L: The role of epidermal growth factor and its receptors in mammalian CNS. Cytokine Growth Factor Rev. 15:147–156. 2004.PubMed/NCBI View Article : Google Scholar
39	Jung N, Kong T, Yu Y, Park H, Lee E, Yoo S, Baek S, Lee S and Kang KS: Immunomodulatory effect of epidermal growth factor secreted by human umbilical cord blood-derived mesenchymal stem cells on atopic dermatitis. Int J Stem Cells. 15:311–323. 2022.PubMed/NCBI View Article : Google Scholar
40	Tang X, Liu H, Yang S, Li Z, Zhong J and Fang R: Epidermal growth factor and intestinal barrier function. Mediators Inflamm. 2016(1927348)2016.PubMed/NCBI View Article : Google Scholar
41	Kawaguchi M, Kamiya Y, Ito J, Fujii T, Hayakawa F, Sakuma N and Fujinami T: Excretion of urinary epidermal growth factor in non-insulin dependent diabetes mellitus. Life Sci. 52:1181–1186. 1993.PubMed/NCBI View Article : Google Scholar
42	Akhtar S and Benter IF: The role of epidermal growth factor receptor in diabetes-induced cardiac dysfunction. Bioimpacts. 3:5–9. 2013.PubMed/NCBI View Article : Google Scholar
43	Cortvrindt C, Speeckaert R, Delanghe JR and Speeckaert MM: Urinary epidermal growth factor: A promising ‘next generation’ biomarker in kidney disease. Am J Nephrol. 53:372–387. 2022.PubMed/NCBI View Article : Google Scholar
44	Borai A, Livingstone C, Abdelaal F, Bawazeer A, Keti V and Ferns G: The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance. Scand J Clin Lab Invest. 71:168–172. 2011.PubMed/NCBI View Article : Google Scholar
45	Liu Y, Yu Q, Luo X, Ye L, Yang L and Cui Y: A microtube-based wearable closed-loop minisystem for diabetes management. Research (Wash D C). 2022(9870637)2022.PubMed/NCBI View Article : Google Scholar
46	Liu Y, Wang H, Wang Y and Xue LX: Annual advances of integrative pharmacology in 2021. Tradit Med Re. 7(57)2022.
47	Fu LH, Qi C, Sun T, Huang K, Lin J and Huang P: Glucose oxidase-instructed biomineralization of calcium-based biomaterials for biomedical applications. Exploration (Beijing). 3(20210110)2023.PubMed/NCBI View Article : Google Scholar
48	Kristófi R and Eriksson JW: Metformin as an anti-inflammatory agent: A short review. J Endocrinol. 251:R11–R22. 2021.PubMed/NCBI View Article : Google Scholar